Opinion: Biogen’s good news on aducanumab could ‘open the floodgates’ for Alzheimer’s drugs
ADOBE
Biogen's positive re-analyses of the aducanumab data represent a key proof of concept: a drug can meaningfully affect clinical symptoms in Alzheimer’s.
Suscribirse a:
Enviar comentarios (Atom)
.png)
No hay comentarios:
Publicar un comentario